Midtown Urology Associates Honored as Third Practice Nationwide To Have Two Physicians Designated as UroLift Center of Excellence

Share Article

Designation Recognizes Drs. Michael Trotter and Brian Mazzarella’s Commitment to Exemplary Care, Deep UroLift Experience in Men with Enlarged Prostate.

News Image
The UroLift System has fundamentally changed how we treat patients suffering bothersome BPH symptoms.

Midtown Urology Associates today announced that Drs. Michael Trotter and Brian Mazzarella of Midtown Urology Associates have been designated as UroLift® Centers of Excellence. The designation recognizes that Dr. Trotter and Dr. Mazzarella have demonstrated a commitment to exemplary care for men suffering from urinary tract symptoms due to benign prostatic hyperplasia (BPH) and have achieved a high level of training and experience with the UroLift System. Midtown Urology Associates is one of only three practices in the U.S. to have two physicians within the same practice earn this distinction.

“The UroLift System is a breakthrough minimally invasive treatment that takes less than an hour and offers multiple benefits for men with enlarged prostate – no cutting, heating, or removal of tissue, minimal downtime, no compromise of sexual function, and no need for continued medications,” said Dr. Trotter. “The UroLift System has fundamentally changed how we treat patients suffering bothersome BPH symptoms. We are proud to be national leaders in treating patients with this durable and effective treatment,” added Dr. Mazzarella.

Nearly 40 million men in the United States are affected by BPH. This condition occurs as the prostate gland that surrounds the male urethra becomes enlarged, exerting pressure on the urethra and restricting or blocking urine flow. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

Medications can be helpful in relieving symptoms for some men, but patients must continue taking them long-term to maintain the effects. Some patients may suffer side effects including dizziness, headaches, or sexual dysfunction. And some may not get adequate relief of their symptoms. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

To schedule a consultation with Midtown Urology Associates, please call 512-451-7935.

About the UroLift System
NeoTract Interventional Urology’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About Midtown Urology
Midtown Urology Associates strives to provide each and every patient with comprehensive and timely state-of-the-art medical care. We pride ourselves on having highly trained and skilled urology professionals with a heightened focus on excellent customer service, compassionate care, advanced technology, convenience and an overall focus that includes operating our practice in a fiscally and ethically responsible manner. Our number one priority is to provide excellent care for each one our patients. Learn more at http://www.austinmidtownurology.com.

Media Contact:
Amy Cramer

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicole Hill
NeoTract Inc.
+1 (925) 201-8285
Email >
Visit website